Orbimed Advisors LLC

Orbimed Advisors LLC, a DE Limited Liability Company, employs 91 people, 60 of whom serve in advisory roles within the firm. Though the number of clients the firm serves is not disclosed, it has been registered with the U.S. Securities and Exchange Commission for nearly two decades. As of their last status approval in April 2002, Orbimed Advisors LLC remains in good standing.

• ALEXANDER MATTHEW COOPER

  GENERAL COUNSEL owns less than 5%

• CARL LEE GORDON

  MEMBER owns more than 25% but less than 50%

• CHARLES SCOTLAND STEVENS

  MEMBER owns less than 5%

• DOUGLAS W. COON

  CHIEF COMPLIANCE OFFICER owns less than 5%

• GEOFFREY CHE-CHANG HSU

  MEMBER owns more than 5% but less than 10%

• JONATHAN TODD SILVERSTEIN

  MEMBER owns more than 10% but less than 25%

• SAM BLOCK III

  CHIEF FINANCIAL OFFICER owns less than 5%

• SVEN HEINZ BORHO

  MEMBER owns more than 25% but less than 50%

• WILLIAM CARTER NEILD

  MEMBER owns more than 10% but less than 25%

• GOLDMAN SACHS & CO. LLC
  United States
• J.P. MORGAN CLEARING CORP.
  United States

• Terranum Capital LLC
• Cornell Capital LLC
• Atalan Capital Partners LP
• TRG Management LP
• Altum Capital Management LLC
• Nexthera Capital LP
• VIS Advisors LP
• Kenmar Preferred Investments LLC
• Spire Capital Management LLC
• AEA QP Advisers LLC

• Orbimed Advisors LLC Q3 2022 vs. Q4 2022: An In-Depth Comparison of 13F Holdings

• ASCENDIS PHARMA A S $442,944k
• TRICIDA INC $438,569k
• BOSTON SCIENTIFIC $290,222k
• ALEXION PHARMACEUTICALS INC CO $252,279k
• ALECTOR INC $250,464k
• MERCK & CO INC $215,503k
• PREVAIL THERAPEUTICS INC COM $182,457k
• Vertex Pharmaceuticals Inc $178,484k
• Neurocrine Biosciences Inc. $154,777k
• Iovance Biotherapeutics Inc $136,045k